These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26002552)

  • 1. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
    Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
    Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
    Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
    J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photochemical internalization (PCI) of HER2-targeted toxins: synergy is dependent on the treatment sequence.
    Berstad MB; Weyergang A; Berg K
    Biochim Biophys Acta; 2012 Dec; 1820(12):1849-58. PubMed ID: 22981913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
    Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
    PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.
    Zdobnova T; Sokolova E; Stremovskiy O; Karpenko D; Telford W; Turchin I; Balalaeva I; Deyev S
    Oncotarget; 2015 Oct; 6(31):30919-28. PubMed ID: 26436696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.
    Mironova KE; Proshkina GM; Ryabova AV; Stremovskiy OA; Lukyanov SA; Petrov RV; Deyev SM
    Theranostics; 2013; 3(11):831-40. PubMed ID: 24312153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
    Jiao P; Zhang J; Dong Y; Wei D; Ren Y
    Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling.
    Montero JC; García-Alonso S; Ocaña A; Pandiella A
    Oncotarget; 2015 Oct; 6(30):30057-71. PubMed ID: 26336133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
    Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
    Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
    Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Light-enhanced VEGF
    Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
    J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.